Literature DB >> 22669948

The SH2B1 adaptor protein associates with a proximal region of the erythropoietin receptor.

Mojib Javadi1, Edda Hofstätter, Natalie Stickle, Bryan K Beattie, Robert Jaster, Christin Carter-Su, Dwayne L Barber.   

Abstract

Gene targeting experiments have shown that the cytokine erythropoietin (EPO), its cognate erythropoietin receptor (EPO-R), and associated Janus tyrosine kinase, JAK2, are all essential for erythropoiesis. Structural-functional and murine knock-in experiments have suggested that EPO-R Tyr-343 is important in EPO-mediated mitogenesis. Although Stat5 binds to EPO-R phosphotyrosine 343, the initial Stat5-deficient mice did not have profound erythroid abnormalities suggesting that additional Src homology 2 (SH2) domain-containing effectors may bind to EPO-R Tyr-343 and couple to downstream signaling pathways. We have utilized cloning of ligand target (COLT) screening to demonstrate that EPO-R Tyr(P)-343 and Tyr(P)-401 bind to the SH2 domain-containing adaptor protein SH2B1β. Immunoprecipitation and in vitro mixing experiments reveal that EPO-R binds to SH2B1 in an SH2 domain-dependent manner and that the sequence that confers SH2B1 binding to the EPO-R is pYXXL. Previous studies have shown that SH2B1 binds directly to JAK2, but we show that in hematopoietic cells, SH2B1β preferentially associates with the EPO-R. SH2B1 is capable of constitutive association with EPO-R, which is necessary for its optimal SH2-dependent recruitment to EPO-R-Tyr(P)-343/Tyr(P)-401. We also demonstrate that SH2B1 is responsive to EPO stimulation and becomes phosphorylated, most likely on serines/threonines, in an EPO dose- and time-dependent manner. In the absence of SH2B1, we observe enhanced activation of signaling pathways downstream of the EPO-R, indicating that SH2B1 is a negative regulator of EPO signaling.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22669948      PMCID: PMC3406707          DOI: 10.1074/jbc.M112.382721

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

1.  Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts.

Authors:  M Socolovsky; H Nam; M D Fleming; V H Haase; C Brugnara; H F Lodish
Journal:  Blood       Date:  2001-12-01       Impact factor: 22.113

2.  SH2-B and APS are multimeric adapters that augment TrkA signaling.

Authors:  X Qian; D D Ginty
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

3.  Phosphorylation controls a dual-function polybasic nuclear localization sequence in the adapter protein SH2B1β to regulate its cellular function and distribution.

Authors:  Travis J Maures; Hsiao-Wen Su; Lawrence S Argetsinger; Sergio Grinstein; Christin Carter-Su
Journal:  J Cell Sci       Date:  2011-04-12       Impact factor: 5.285

4.  The distal region and receptor tyrosines of the Epo receptor are non-essential for in vivo erythropoiesis.

Authors:  H Zang; K Sato; H Nakajima; C McKay; P A Ney; J N Ihle
Journal:  EMBO J       Date:  2001-06-15       Impact factor: 11.598

5.  A common epitope is shared by activated signal transducer and activator of transcription-5 (STAT5) and the phosphorylated erythropoietin receptor: implications for the docking model of STAT activation.

Authors:  D L Barber; B K Beattie; J M Mason; M H Nguyen; M Yoakim; B G Neel; A D D'Andrea; D A Frank
Journal:  Blood       Date:  2001-04-15       Impact factor: 22.113

6.  The SH2 inositol 5-phosphatase Ship1 is recruited in an SH2-dependent manner to the erythropoietin receptor.

Authors:  J M Mason; B K Beattie; Q Liu; D J Dumont; D L Barber
Journal:  J Biol Chem       Date:  2000-02-11       Impact factor: 5.157

7.  Protein kinase C alpha controls erythropoietin receptor signaling.

Authors:  M von Lindern; M Parren-van Amelsvoort; T van Dijk; E Deiner; E van den Akker; S van Emst-de Vries; P Willems; H Beug; B Löwenberg
Journal:  J Biol Chem       Date:  2000-11-03       Impact factor: 5.157

8.  Differential binding to and regulation of JAK2 by the SH2 domain and N-terminal region of SH2-bbeta.

Authors:  L Rui; D R Gunter; J Herrington; C Carter-Su
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

9.  Essential role of PSM/SH2-B variants in insulin receptor catalytic activation and the resulting cellular responses.

Authors:  Manchao Zhang; Youping Deng; Ruchi Tandon; Cheng Bai; Heimo Riedel
Journal:  J Cell Biochem       Date:  2008-01-01       Impact factor: 4.429

10.  Hematopoietic-specific Stat5-null mice display microcytic hypochromic anemia associated with reduced transferrin receptor gene expression.

Authors:  Bing-Mei Zhu; Sara K McLaughlin; Risu Na; Jie Liu; Yongzhi Cui; Cyril Martin; Akiko Kimura; Gertraud W Robinson; Nancy C Andrews; Lothar Hennighausen
Journal:  Blood       Date:  2008-06-13       Impact factor: 22.113

View more
  11 in total

1.  Circulating SH2B1 is associated with an increased risk of gastric cancer.

Authors:  Bo Liu; Feng Li; Hong-Peng Zhao; Jing-Bo Chen; Yu-Peng Li; Hai-Hua Yu
Journal:  Oncol Lett       Date:  2018-03-07       Impact factor: 2.967

Review 2.  SH2B1 regulation of energy balance, body weight, and glucose metabolism.

Authors:  Liangyou Rui
Journal:  World J Diabetes       Date:  2014-08-15

3.  Natural Selection on Genes Related to Cardiovascular Health in High-Altitude Adapted Andeans.

Authors:  Jacob E Crawford; Ricardo Amaru; Jihyun Song; Colleen G Julian; Fernando Racimo; Jade Yu Cheng; Xiuqing Guo; Jie Yao; Bharath Ambale-Venkatesh; João A Lima; Jerome I Rotter; Josef Stehlik; Lorna G Moore; Josef T Prchal; Rasmus Nielsen
Journal:  Am J Hum Genet       Date:  2017-11-02       Impact factor: 11.025

Review 4.  The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders.

Authors:  N Maslah; B Cassinat; E Verger; J-J Kiladjian; L Velazquez
Journal:  Leukemia       Date:  2017-05-09       Impact factor: 11.528

5.  SH2B1β interacts with STAT3 and enhances fibroblast growth factor 1-induced gene expression during neuronal differentiation.

Authors:  Yu-Jung Chang; Kuan-Wei Chen; Ching-Jen Chen; Ming-Hsing Lin; Yuh-Ju Sun; Jia-Lin Lee; Ing-Ming Chiu; Linyi Chen
Journal:  Mol Cell Biol       Date:  2014-01-06       Impact factor: 4.272

Review 6.  Unravelling the potential neuroprotective facets of erythropoietin for the treatment of Alzheimer's disease.

Authors:  Dapinder Kaur; Tapan Behl; Aayush Sehgal; Sukhbir Singh; Neelam Sharma; Vishnu Nayak Badavath; Syed Shams Ul Hassan; Mohammad Mehedi Hasan; Saurabh Bhatia; Ahmed Al-Harassi; Haroon Khan; Simona Bungau
Journal:  Metab Brain Dis       Date:  2021-08-26       Impact factor: 3.584

7.  Hepatic SH2B1 and SH2B2 regulate liver lipid metabolism and VLDL secretion in mice.

Authors:  Liang Sheng; Yan Liu; Lin Jiang; Zheng Chen; Yingjiang Zhou; Kae Won Cho; Liangyou Rui
Journal:  PLoS One       Date:  2013-12-17       Impact factor: 3.240

Review 8.  Neuroprotective effects of erythropoietin on neurodegenerative and ischemic brain diseases: the role of erythropoietin receptor.

Authors:  Carolina Castillo Hernández; Carlos Felipe Burgos; Angela Hidalgo Gajardo; Tiare Silva-Grecchi; Javiera Gavilan; Jorge Roberto Toledo; Jorge Fuentealba
Journal:  Neural Regen Res       Date:  2017-09       Impact factor: 5.135

9.  Enu mutagenesis identifies a novel platelet phenotype in a loss-of-function Jak2 allele.

Authors:  Nicole M Anderson; Mojib Javadi; Elizabeth Berndl; Zorana Berberovic; Monica L Bailey; Kai Huang; Ann M Flenniken; Lucy R Osborne; S Lee Adamson; Janet Rossant; Christin Carter-Su; Chen Wang; Kelly M McNagny; Robert F Paulson; Mark D Minden; William L Stanford; Dwayne L Barber
Journal:  PLoS One       Date:  2013-09-25       Impact factor: 3.240

Review 10.  JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms.

Authors:  Karoline Gäbler; Iris Behrmann; Claude Haan
Journal:  JAKSTAT       Date:  2013-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.